65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis Announces Changes to the Executive Committee
November 01, 2023 02:20 ET | Spexis AG
Spexis Announces Changes to the Executive Committee
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis to host business update conference call on October 9, 2023
October 06, 2023 01:30 ET | Spexis AG
Spexis to host business update conference call on October 9, 2023
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis provides business update and announces financial results for the first half of 2023
September 29, 2023 01:30 ET | Spexis AG
Spexis provides business update and announces financial results for the first half of 2023
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
September 28, 2023 01:30 ET | Spexis AG
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
August 15, 2023 01:15 ET | Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle...
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
June 30, 2023 01:15 ET | Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and...
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
June 07, 2023 01:15 ET | Spexis AG
ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis provides business update and announces financial results for the full year 2022
May 30, 2023 01:15 ET | Spexis AG
Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in...
65f904ea-1192-4a36-be11-d574ccffe4fa.png
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
April 18, 2023 02:23 ET | Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment...
Spexis logo.png
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
February 08, 2023 02:00 ET | Spexis AG
Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 development costs, including those involving both COPILOT and COPASGI...